secwatch.observer — SEC 8-K summary
======================================

Issuer:     Penumbra Inc (PEN)
CIK:        0001321732
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001321732-24-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Penumbra Q4 revenue $284.7M (+28.7%); thrombectomy sales up 42.4%
-----------------------------------------------------------------

- Revenue of $284.7M in Q4 2023, up 28.7% YoY; full-year $1,058.5M, up 25.0%.
- Thrombectomy product revenue $190.8M in Q4 (+42.4%); full-year $677.3M (+32.5%).
- Net income $54.2M in Q4; adjusted EBITDA margin 18.8%; cash and investments up $40.3M.
- FY 2024 guidance: total revenue growth 16-20%, US thrombectomy growth 27-30%, gross margin +100-150bps.
- Non-GAAP operating income $37.4M in Q4; full-year $101.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321732/000132173224000023/0001321732-24-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321732/000132173224000023/pen-20240222.htm
  HTML page:      https://secwatch.observer/filing/0001321732-24-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer